Record sales and profitability were achieved in 2025, led by Cystatin C’s 32% growth and strong US expansion. A new exclusive partnership and high-sensitivity technology project were announced, while NT-proBNP assay development faced a setback.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.